Valuation: StemRIM

Market Cap 19.43B 120M 105M 96.88M 89.75M 170M 11.38B 173M 1.15B 450M 5.61B 450M 440M P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 12.44B 76.66M 67.24M 62.01M 57.45M 109M 7.28B 111M 737M 288M 3.59B 288M 282M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
47.55%
Yield 2024 *
-
Yield 2025 -
1 day+0.98%
1 week-5.20%
Current month-4.32%
1 month+5.08%
3 months+2.31%
6 months+14.81%
Current year+17.87%
1 week 304
Extreme 304
328
1 month 273
Extreme 273
330
Current year 260
Extreme 260
330
1 year 246
Extreme 246
333
3 years 246
Extreme 246
965
5 years 246
Extreme 246
1,518
10 years 246
Extreme 246
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 30/09/2022
Chief Executive Officer 58 24/10/2023
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 58 28/02/2019
Director/Board Member 54 30/09/2019
Director/Board Member 66 31/01/2007
Change 5-day change 1-year change 3-year change Capi.($)
+0.98%-5.20%+1.31%-64.65% 119M
+4.07%+8.45%+25.67%-2.34% 66.11B
-0.24%-3.13%+49.38%+223.97% 55.3B
+1.21%+42.20%+42.20%+42.20% 42.44B
-0.21%+7.44%-48.93%-54.50% 41.28B
-2.48%+13.91%+166.79%-32.89% 32.46B
-1.32%-4.79%+58.07%-25.22% 30.78B
+2.10%+4.14%+75.49%+90.19% 23.1B
-3.65%+8.93%+1.16%+184.50% 20.06B
-0.04%+3.85%+67.76%+135.89% 17.19B
Average +0.23%+4.14%+43.89%+49.71% 32.88B
Weighted average by Cap. +0.65%+4.93%+43.58%+54.86%

Financials

2024 2025
Net sales - -
Net income -2.02B -12.46M -10.93M -10.08M -9.34M -17.7M -1.18B -18.01M -120M -46.87M -584M -46.81M -45.8M -1.93B -11.89M -10.43M -9.62M -8.91M -16.89M -1.13B -17.18M -114M -44.71M -557M -44.65M -43.69M
Net Debt -8.41B -51.84M -45.46M -41.93M -38.85M -73.63M -4.93B -74.9M -499M -195M -2.43B -195M -190M -6.99B -43.11M -37.81M -34.87M -32.31M -61.23M -4.1B -62.29M -415M -162M -2.02B -162M -158M
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
45
Date Price Change Volume
07/07/26 JP¥310.00 +0.98% 161,700
06/07/26 JP¥307.00 -1.92% 228,200
03/07/26 JP¥313.00 +0.97% 209,300
02/07/26 JP¥310.00 -2.52% 172,900
01/07/26 JP¥318.00 -1.85% 301,500
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4599 Stock